Statement: the primary trial had a total of 3 patients experiencing Pancreatic Cancer, the secondary trial had 0.
Primary_evidence: Adverse Events 1:   Total: 103/1408 (7.32%)   Anaemia 1/1408 (0.07%)   Angina pectoris 1/1408 (0.07%)   Myocardial infarction 1/1408 (0.07%)   Atrial fibrillation 0/1408 (0.00%)   Sinus tachycardia 0/1408 (0.00%)   Tachycardia 0/1408 (0.00%)   Vertigo 0/1408 (0.00%)   Diarrhoea 22/1408 (1.56%)   Vomiting 12/1408 (0.85%)   Nausea 4/1408 (0.28%)   Abdominal pain 2/1408 (0.14%)   Pancreatitis 2/1408 (0.14%) Adverse Events 2:   Total: 85/1408 (6.04%)   Anaemia 1/1408 (0.07%)   Angina pectoris 0/1408 (0.00%)   Myocardial infarction 1/1408 (0.07%)   Atrial fibrillation 1/1408 (0.07%)   Sinus tachycardia 1/1408 (0.07%)   Tachycardia 1/1408 (0.07%)   Vertigo 1/1408 (0.07%)   Diarrhoea 1/1408 (0.07%)   Vomiting 1/1408 (0.07%)   Nausea 1/1408 (0.07%)   Abdominal pain 0/1408 (0.00%)   Pancreatitis 1/1408 (0.07%)
Secondary_evidence: Adverse Events 1:   Total: 46/170 (27.06%)   Anaemia 1/170 (0.59%)   Febrile neutropenia 1/170 (0.59%)   Cardiac tamponade 1/170 (0.59%)   Myocarditis 1/170 (0.59%)   Pericardial effusion 2/170 (1.18%)   Pericarditis 1/170 (0.59%)   Colitis 1/170 (0.59%)   Constipation 1/170 (0.59%)   Diarrhoea 0/170 (0.00%)   Gastroenteritis eosinophilic 0/170 (0.00%)   Intestinal obstruction 0/170 (0.00%) Adverse Events 2:   Total: 0/1 (0.00%)   Anaemia 0/1 (0.00%)   Febrile neutropenia 0/1 (0.00%)   Cardiac tamponade 0/1 (0.00%)   Myocarditis 0/1 (0.00%)   Pericardial effusion 0/1 (0.00%)   Pericarditis 0/1 (0.00%)   Colitis 0/1 (0.00%)   Constipation 0/1 (0.00%)   Diarrhoea 0/1 (0.00%)   Gastroenteritis eosinophilic 0/1 (0.00%)   Intestinal obstruction 0/1 (0.00%)   Nausea 0/1 (0.00%)